Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

NCT05900089 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT05900089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05900089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
May 30, 2023
Completion date
June 1, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma